Seeking Alpha
27 Oct 2026, 11:40 UTC · 5h ago
Carl Zeiss Meditec: Why The Market Is Finally Recognizing The Recovery
Impact · against what's priced in
The article is not a catalyst for AFX.DE as the recovery thesis is already being reflected in the stock's 50% rebound. The projected EBITA margin recovery and EPS targets are viewed as milestones for the existing recovery trend rather than new surprises.
- AFX.DE+0.10
No priced-in read yet
- In context
While the analyst targets an EBITA margin of 15% and EPS above €2.5 post-2027, the stock's 50% rebound from early 2026 lows suggests the market has already begun pricing in this recovery.
Read from the article alone
Top 1 mover · tap to explore
